HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation

Files in This Item:
IJH91-2_310-321.pdf460.51 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/49669

Title: Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation
Authors: Kondo, Takeshi Browse this author →KAKEN DB
Yasumoto, Atsushi Browse this author
Arita, Kotaro Browse this author
Sugita, Jun-ichi Browse this author
Shigematsu, Akio Browse this author
Okada, Kohei Browse this author
Takahata, Mutsumi Browse this author
Onozawa, Masahiro Browse this author →KAKEN DB
Kahata, Kaoru Browse this author
Takeda, Yukari Browse this author
Obara, Masato Browse this author
Yamamoto, Satoshi Browse this author
Endo, Tomoyuki Browse this author
Nishio, Mitsufumi Browse this author →KAKEN DB
Sato, Norihiro Browse this author
Tanaka, Junji Browse this author →KAKEN DB
Hashino, Satoshi Browse this author →KAKEN DB
Koike, Takao Browse this author →KAKEN DB
Asaka, Masahiro Browse this author →KAKEN DB
Imamura, Masahiro Browse this author →KAKEN DB
Keywords: AML
Favorable karyotype
RIST
Issue Date: Mar-2010
Publisher: Springer Japan
Journal Title: International Journal of Hematology
Volume: 91
Issue: 2
Start Page: 310
End Page: 321
Publisher DOI: 10.1007/s12185-009-0487-y
PMID: 20087795
Abstract: Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy. If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option. Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks. The outcome of allo-HSCT for AML patients with favorable cytogenetics seemed to be superior to that for AML patients with intermediate cytogenetics. In AML patients with favorable cytogenetics, the 3-year overall survival (OS) and relapse-free survival (RFS) rates were 88% and 76%, respectively, in the RIST group. Both the 3-year OS and RFS rates were 81% in the conventional stem cell transplantation (CST) group. The outcome of RIST for AML patients with favorable cytogenetics was comparable to that for patients who received CST despite the more advanced age and greater organ dysfunction in RIST group than in CST group. None of the patients died within 90 days after RIST. Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST. Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.
Rights: The final publication is available at www.springerlink.com
Type: article (author version)
URI: http://hdl.handle.net/2115/49669
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 近藤 健

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University